Clinical Trials Logo
  1. Home
  2. Progesterone
  3. NCT05742503
  4. Details
NCT05742503 Clinical Trial

Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

Progesterone Clinical Trial

Official title:
Effects of Different Progesterone Containing Contraceptive Methods on Safety and Endogenous Progesterone Level

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05742503
Other study ID # 36035/11/22
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 30, 2021
Est. completion date March 30, 2022

Study information
Verified date February 2023
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level

Description:

Progestogen-only' contraceptives are presented as injections, implants, oral formulations, hormone-releasing intrauterine methods and emergency contraceptives. These substances could be used by females who are breastfeeding or have other contraindications to estrogen treatment, including those who are immediately postpartum, have thalassemia, sickle-cell disease, gallbladder disease, or currently experiencing thrombo-embolic disorders, valvular heart disease, ischemic heart disease. Intrauterine, injectable methods and contraceptive implants named as long-acting reversible contraceptives (LARC) are the more efficient reversible contraceptive approaches are highly effective, longer-acting contraceptive methods levels.

Recruitment information / eligibility
Status Completed
Enrollment 80
Est. completion date March 30, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria: - 80 healthy fertile females - 20-35 years - With normal menstrual history - Had at least one offspring after spontaneous pregnancy Exclusion Criteria: - Any disease affects uterus (uterine tumors fibroids, endometriosis, prolapse, or tuberculosis). - Ovarian tumors - submucous myoma - irregular menstrual cycle - past or family history of breast disease - Diabetic patients, - medication affecting reproductive or metabolic functions. - endometrial thickness <7 mm on the secretory transformation day - history of spontaneous abortions - history of embryo transfer failure on over three occasions - Patients had cortisol medications - patients who received radiological treatment

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Depo-Provera
Injectable progesterone
• Implanon
Etonogestrel implant
• Norgestrel
Pill containing progesterone
• Mirena
Levonorgestrel-releasing intra-uterine drug (IUD)

Locations
Country Name City State
Egypt Ahmed Ossman Tanta El-Gharbia

Sponsors (1)
Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Assess the effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level The effect of different progesterone containing contraceptive methods on safety and endogenous progesterone level will be recorded Six mounths
See also
  Status Clinical Trial Phase
Completed NCT03340701 - Pharmacokinetics of Progesterone in Pregnancy Phase 1
Completed NCT04535973 - Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
Completed NCT03740568 - Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes. N/A
Terminated NCT04140968 - Progesterone and Resting Energy Expenditure Phase 4
Completed NCT03677336 - Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI Phase 4
Not yet recruiting NCT03456570 - The Efficacy of Progestins in Treatment of Functional Ovarian Cyst Early Phase 1
Completed NCT02323347 - Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer N/A
Completed NCT00264407 - Neural Changes in the Aging Auditory System Phase 1
Recruiting NCT04124913 - Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles Phase 4
Completed NCT03734770 - Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support N/A
Completed NCT04253470 - Debate on Progesterone Elevation on the Day of Triggering
Completed NCT04769401 - Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle N/A
Recruiting NCT05481684 - The Importance of Embryo Transfer Day Progesterone Value in Natural Cycle Frozen Embryo Transfers and the Evaluation of the Effect of Rescue Therapy on Pregnancy Outcomes in Patients With Low Progesterone Levels N/A
Completed NCT05276531 - Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support N/A